Severe SARS-CoV-2 patients develop a higher specific T-cell response.

ABSTRACT:

Objectives

Assessment of the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for studying long-term immunity and vaccine strategies. We quantified IFNγ-secreting T cells reactive against the main viral SARS-CoV-2 antigens using a standardised enzyme-linked immunospot assay (ELISpot).

Methods

Overlapping peptide pools built from the sequences of M, N and S viral proteins and a mix (MNS) were used as antigens. Using IFNγ T-CoV-Spot assay, we assessed T-cell and antibody responses in mild, moderate and severe SARS-CoV-2 patients and in control samples collected before the outbreak.

Results

Specific T cells were assessed in 60 consecutive patients (mild, n = 26; moderate, n = 10; and severe patients, <

SUBMITTER: Demaret J 

PROVIDER: S-EPMC7757425 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature